TNFRSF8 positive
|
HL
|
TNFRSF8 positive
|
HL
|
brentuximab vedotin Sensitive: A1 - Approval
|
brentuximab vedotin Sensitive: A1 - Approval
|
TNFRSF8 positive
|
Cutaneous T-cell Lymphoma
|
TNFRSF8 positive
|
Cutaneous T-cell Lymphoma
|
brentuximab vedotin Sensitive: A1 - Approval
|
brentuximab vedotin Sensitive: A1 - Approval
|
TNFRSF8 positive
|
Diffuse Large B Cell Lymphoma
|
TNFRSF8 positive
|
Diffuse Large B Cell Lymphoma
|
brentuximab vedotin Sensitive: A2 - Guideline
|
brentuximab vedotin Sensitive: A2 - Guideline
|
TNFRSF8 positive
|
Peripheral T-cell Lymphoma
|
TNFRSF8 positive
|
Peripheral T-cell Lymphoma
|
brentuximab vedotin Sensitive: A2 - Guideline
|
brentuximab vedotin Sensitive: A2 - Guideline
|
TNFRSF8 positive
|
NHL
|
TNFRSF8 positive
|
NHL
|
TT11 Sensitive: C2 – Inclusion Criteria
|
TT11 Sensitive: C2 – Inclusion Criteria
|
TNFRSF8 positive
|
Lymphoma
|
TNFRSF8 positive
|
Lymphoma
|
AFM13 Sensitive: C2 – Inclusion Criteria
|
AFM13 Sensitive: C2 – Inclusion Criteria
|
TNFRSF8 positive
|
HL
|
TNFRSF8 positive
|
HL
|
AFM13 Sensitive: C2 – Inclusion Criteria
|
AFM13 Sensitive: C2 – Inclusion Criteria
|
TNFRSF8 positive
|
HL
|
TNFRSF8 positive
|
HL
|
TT11 Sensitive: C3 – Early Trials
|
TT11 Sensitive: C3 – Early Trials
|
TNFRSF8 positive
|
Peripheral T-cell Lymphoma
|
TNFRSF8 positive
|
Peripheral T-cell Lymphoma
|
BV-ICE Sensitive: C3 – Early Trials
|
BV-ICE Sensitive: C3 – Early Trials
|
TNFRSF8 positive
|
Lymphoma
|
TNFRSF8 positive
|
Lymphoma
|
T-lymphocyte cell therapy Sensitive: D – Preclinical
|
T-lymphocyte cell therapy Sensitive: D – Preclinical
|